Ticker

AUSTIN, Texas & IRVINE, Calif.--(BUSINESS WIRE)--Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN), a clinical stage biotechnology company developing immune-modulating therapies for the management and treatment of life-threatening conditions, today announced a strategic partnership to incorporate Natera's Prospera kidney transplant…

Eledon Pharmaceuticals, Inc. (ELDN) Discusses Updated Long-term Data From Phase 2 BESTOW Clinical Trial in Kidney Transplantation Transcript

Eledon Presents Long-Term Phase 2 BESTOW Results at ATC Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart

Here is how Eledon Pharmaceuticals, Inc. (ELDN) and Galderma Group AG - Unsponsored ADR (GALDY) have performed compared to their sector so far this year.

– All 12 patients in study (100%) achieved insulin independence, producing their own insulin and no longer requiring exogenous insulin therapy to manage their T1D – All 12 patients also achieved an HbA1c below 6.5%, with a mean most recent HbA1c of approximately 5.4%, representing an approximately 2.6% average improvement in HbA1c from baseline – No severe hypoglycemic episodes were reported post-transplant,…